B. Rini
Pulmonary and Respiratory Medicine · 2006–2020
A researcher in the Science corpus: 20 papers; trusts 7 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Pulmonary and Respiratory Medicine — 128 citations into it
- Oncology — 96 citations into it
- Immunology — 41 citations into it
- Surgery — 23 citations into it
- Epidemiology — 19 citations into it
Whom B. Rini trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts B. Rini overall
Papers from B. Rini's perspective
Ordered by how strongly the researchers B. Rini trusts endorse each paper. Same corpus, a different order for every researcher.
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. (New England Journal of Medicine)
- Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion (Nature Medicine)
- Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. (The Lancet)
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study (The Lancet Oncology)
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (The Lancet Oncology)
- Cancer despite immunosurveillance: immunoselection and immunosubversion (Nature reviews. Immunology)
- Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape (Science Translational Medicine)
- Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. (Journal of Clinical Oncology)
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria (Clinical Cancer Research)
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
Their papers
- Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. (2006) — 1,640 citations
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. (2011) — 1,754 citations
- Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. (2016) — 854 citations
- Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. (2009) — 1,988 citations
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study (2020) — 1,555 citations
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma (2019) — 2,674 citations
- Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised phase 3 trial (2019) — 639 citations
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma (2019) — 2,035 citations
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. (2019) — 839 citations
- Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma (2018) — 3,808 citations
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma (2018) — 1,089 citations
- Treatment of renal cell carcinoma: Current status and future directions (2017) — 730 citations
- Cabozantinib versus everolimus in advanced renal cell carcinoma (2015) — 1,101 citations
- Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial (2014) — 1,015 citations
- Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. (2013) — 714 citations
- External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. (2013) — 914 citations
- Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. (2010) — 778 citations
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients (2009) — 870 citations
- Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. (2008) — 829 citations
- Sunitinib in patients with metastatic renal cell carcinoma. (2006) — 1,248 citations